miR-30e-5p as predictor of generalization in ocular myasthenia gravis.


Journal

Annals of clinical and translational neurology
ISSN: 2328-9503
Titre abrégé: Ann Clin Transl Neurol
Pays: United States
ID NLM: 101623278

Informations de publication

Date de publication:
02 2019
Historique:
received: 29 07 2018
revised: 09 10 2018
accepted: 12 10 2018
entrez: 9 3 2019
pubmed: 9 3 2019
medline: 9 3 2019
Statut: epublish

Résumé

To determine a predictive factor for the risk of conversion from ocular myasthenia gravis (OMG) to generalized MG (GMG) in a prospective study. RNA was isolated from serum samples and detection of microRNA (miRNA) expression analyzed with qPCR. In the discovery set, 179 human miRNAs were assayed for profiling of five OMG patients and four age- and gender-matched healthy controls. Based on the specific accumulation pattern of 19 miRNAs from the discovery set, in addition to miRNAs previously found elevated in generalized MG (GMG; miR-150-5p and miR-30e-5p), 21 miRNAs were subsequently analyzed in a validation cohort of 83 OMG patients (82 immunosuppression treatment naive; 49 male) within 3 months of diagnosis and at a follow-up visit (median duration 28 months from first visit). Thirteen patients generalized 14.8 ± 12.0 months after the diagnosis and the majority (85%) belonged to the late onset MG group. Two miRNAs were significantly higher in secondary GMG (SGMG) patients compared to OMG patients with late onset MG: miR-30e-5p (9.1 ± 0.5 vs. 6.3 ± 0.9; This is the first study to describe a potential predictive factor associated with the risk of generalization for patients with OMG. Raised levels (>8) of miR-30e-5p at initial presentation in patients with ocular MG symptoms, give a predictive cut-off for subsequent generalization of 96-100%.

Identifiants

pubmed: 30847357
doi: 10.1002/acn3.692
pii: ACN3692
pmc: PMC6389736
doi:

Substances chimiques

MIRN30b microRNA, human 0
MicroRNAs 0
Receptors, Cholinergic 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Pagination

243-251

Déclaration de conflit d'intérêts

None declared.

Références

Ann Neurol. 1983 Nov;14(5):516-9
pubmed: 6651238
J Neurol. 2009 Aug;256(8):1314-20
pubmed: 19377863
PLoS One. 2014 Mar 17;9(3):e91927
pubmed: 24637658
J Neuroimmunol. 2018 Aug 15;321:164-170
pubmed: 29804819
J Am Geriatr Soc. 2000 Nov;48(11):1442-8
pubmed: 11083321
Sci Rep. 2015 Jul 07;5:11953
pubmed: 26150313
J Clin Immunol. 2013 Apr;33(3):567-76
pubmed: 23196978
Neurosci Lett. 2013 Oct 25;555:85-90
pubmed: 24036458
J Neuroophthalmol. 2003 Dec;23(4):249-50
pubmed: 14663302
Neurol Neuroimmunol Neuroinflamm. 2018 Mar 01;5(3):e450
pubmed: 29511707
Int Immunopharmacol. 2012 Oct;14(2):217-23
pubmed: 22835429
J Neuroophthalmol. 2016 Mar;36(1):98-102
pubmed: 26218625
Neurologist. 2006 Sep;12(5):231-9
pubmed: 16990734
Mol Cell Biol. 2015 May;35(10):1763-76
pubmed: 25755281
Ann Clin Transl Neurol. 2014 Jan;1(1):49-58
pubmed: 25356381
Lancet Neurol. 2009 May;8(5):475-90
pubmed: 19375665
Eur J Neurol. 2014 May;21(5):687-93
pubmed: 24471489
Nat Rev Clin Oncol. 2014 Mar;11(3):145-56
pubmed: 24492836
J Neuroimmunol. 2016 Mar 15;292:21-6
pubmed: 26943954
BMC Neurol. 2010 Jun 18;10:46
pubmed: 20565885
Ann N Y Acad Sci. 2018 Jan;1412(1):33-40
pubmed: 29125182
J Clin Neuromuscul Dis. 2000 Sep;2(1):6-9
pubmed: 19078595
Cell Death Dis. 2013 Oct 10;4:e845
pubmed: 24113179
Brain Behav. 2017 Mar 01;7(4):e00653
pubmed: 28413704
Can J Ophthalmol. 2001 Feb;36(1):26-33
pubmed: 11227387
Clin Immunol. 2016 Mar;164:106-13
pubmed: 26845678
J Neuroophthalmol. 2016 Sep;36(3):252-8
pubmed: 27031125
J Neurol Neurosurg Psychiatry. 1989 Oct;52(10):1121-7
pubmed: 2795037
J Neurol Neurosurg Psychiatry. 2017 Sep;88(9):761-763
pubmed: 28601810
Immunology. 2015 Jan;144(1):1-10
pubmed: 25093579
Curr Neurol Neurosci Rep. 2014 Jan;14(1):421
pubmed: 24272275
Brief Bioinform. 2016 Mar;17(2):204-12
pubmed: 26238539
Cell Mol Life Sci. 2016 May;73(10):2041-51
pubmed: 26943802
Muscle Nerve. 2008 Feb;37(2):141-9
pubmed: 18059039
J Neurol Sci. 2015 Sep 15;356(1-2):90-6
pubmed: 26095457
Lancet Neurol. 2015 Oct;14(10):1023-36
pubmed: 26376969
Int J Neurosci. 2018 Jan;128(1):15-24
pubmed: 28625092
Eur Cytokine Netw. 2015 Sep;26(3):61-6
pubmed: 26845056
Autoimmun Rev. 2016 Dec;15(12):1171-1180
pubmed: 27639156

Auteurs

Liis Sabre (L)

Department of Neuroscience Clinical Neurophysiology Uppsala University Uppsala Sweden.

Paul Maddison (P)

Department of Neurology Nottingham University Hospitals NHS Trust Queens Medical Centre Nottingham Nottinghamshire United Kingdom.

Sui H Wong (SH)

Department of Neuro-ophthalmology Moorfields Eye Hospital NHS Foundation Trust London.

Girija Sadalage (G)

Department of Neurology Nottingham University Hospitals NHS Trust Queens Medical Centre Nottingham Nottinghamshire United Kingdom.

Philip A Ambrose (PA)

Department of Neurology Nottingham University Hospitals NHS Trust Queens Medical Centre Nottingham Nottinghamshire United Kingdom.

Gordon T Plant (GT)

Department of Neuro-ophthalmology Moorfields Eye Hospital NHS Foundation Trust London.

Anna R Punga (AR)

Department of Neuroscience Clinical Neurophysiology Uppsala University Uppsala Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH